Not recruiting yet
Robot-Assisted Hematoma Evacuation With Intrahematoma Tenecteplase for Post-Reperfusion PH2 Hemorrhagic Transformation
NCT07641998 · Beijing Tiantan Hospital · Updated 11 June 2026
- What is being tested
- Robot-assisted stereotactic hematoma aspiration plus intrahematoma tenecteplase
- For
- Hemorrhagic Transformation Stroke
- Kind of study
- Tests a treatment or device on volunteers. Phase 1.
- Who can join
- Ages 18 years to 80 years. About 20 people. The full rules are on the registry page.
- Where
- China
- When
- Starts or started 10 June 2026, ends 30 Dec 2026. Registered 11 June 2026.
- Results
- None posted yet.
In the researchers' words
The purpose of this phase I trial is to evaluate the safety and feasibility of robot-assisted stereotactic minimally invasive hematoma aspiration, followed when eligible by intrahematoma tenecteplase administration, in patients who develop symptomatic supratentorial PH2 hemorrhagic transformation after reperfusion therapy for acute ischemic stroke. The main study questions are whether this strategy is associated with an acceptable early rebleeding risk and whether it can achieve clinically meaningful hematoma reduction with accurate catheter placement and relief of hematoma-related mass effect.
Sites
- Beijing Tiantan Hospital, Capital Medical UniversityBeijing, Beijing Municipality, China